[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647186":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":85,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"QLESP Group","EXPERIMENTAL","Participants receive ultrasound-guided QLESP block with 30 mL of 0.375% ropivacaine (15 mL in the erector spinae fascial plane and 15 mL in the quadratus lumborum-psoas major interfascial plane) after induction of general anesthesia.",[13],"Drug: ropivacaine",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","ACTIVE_COMPARATOR","Participants receive local wound infiltration with 30 mL of 0.375% ropivacaine at the port sites performed by the surgeon at the end of surgery.",[19],"Drug: ropivacaine (local infiltration)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","ropivacaine (local infiltration)","Ultrasound-guided QLESP block with 30 mL of 0.375% ropivacaine (15 mL injected between the erector spinae muscle and the transverse process at L2 level, followed by 15 mL injected between the quadratus lumborum and psoas major muscles) after induction of general anesthesia.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"ropivacaine","Local wound infiltration with 30 mL of 0.375% ropivacaine at the port sites performed by the surgeon at the end of surgery.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Xi Wu","CONTACT","+8615871715431","wu2018whuh@163.com",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430022","China","CN",{"type":46,"coordinates":47},"Point",[48,49],114.26667,30.58333,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":26,"email":55},"You-nian Xu","+8613657263415","xyn0103@hust.edu.cn",{"type":57,"investigatorFullName":33,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100647186","qlesp-block-for-pain-control-in-robotic-partial-nephrectomy-100647186",false,"NCT07704970","QLESP Block for Pain Control in Robotic Partial Nephrectomy","Ultrasound-Guided L2 Level QLESP Block for Postoperative Analgesia in Robot-Assisted Partial Nephrectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 75 years\n* Scheduled for elective robot-assisted partial nephrectomy (RAPN)\n* American Society of Anesthesiologists (ASA) physical status I to III\n* Body mass index (BMI) 18 to 35 kg\u002Fm²\n* Voluntarily signed informed consent form Able to understand pain scoring and use of patient-controlled analgesia (PCA)\n\nExclusion Criteria:\n\n* Language, communication, or comprehension barriers\n* Infection at the intended puncture site\n* Coagulopathy or bleeding diathesis\n* Known allergy or contraindication to local anesthetics or opioids\n* Use of analgesic medications within the past 3 months\n* Peripheral neuropathy\n* Severe cardiac, hepatic, or renal dysfunction\n* Pregnancy or breastfeeding\n* Refusal to participate in the study","ALL","18 Years","80 Years",{"count":70,"type":71},120,"ESTIMATED","INTERVENTIONAL",[74],"NA","The goal of this clinical trial is to learn if an ultrasound-guided nerve block called QLESP works to reduce pain and the need for strong pain medicines after robotic kidney surgery in adults. The main questions it aims to answer are:\n\n1. Does QLESP reduce the total amount of opioid pain medicine participants need in the first 48 hours after surgery?\n2. Does QLESP lower pain scores and improve recovery quality after surgery? Researchers will compare participants who receive QLESP block to participants who receive the same numbing medicine injected only at the surgical wound sites.\n\nParticipants will:\n\n1. Be randomly assigned to receive either QLESP or local wound injection before surgery.\n2. Have a patient-controlled pain pump for 48 hours after surgery.\n3. Complete pain scores and recovery quality questionnaires at 2, 6, 12, 24, 48, and 72 hours after surgery.\n4. Be followed until hospital discharge.",[77,78,79],"Renal Cell Carcinoma (Kidney Cancer)","Postoperative Pain","Nerve Block",[81,82,83,78,84],"Quadratus Lumborum Block","Erector Spinae Plane Block","Robot-Assisted Partial Nephrectomy","Enhanced Recovery After Surgery","NOT_YET_RECRUITING","2026-07-15",{"date":88,"type":89},"2026-07-16","ACTUAL",{"date":91,"type":71},"2026-07-20",{"date":93,"type":71},"2027-03-31",{"name":5,"class":6},1]